Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$12.37 USD
-0.11 (-0.88%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $12.38 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Enanta Pharmaceuticals, Inc falls in the month of September.
All items in Millions except Per Share data.
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 370 | 249 | 244 | 387 | 335 |
Receivables | 40 | 49 | 61 | 23 | 51 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 13 | 13 | 14 | 27 | 15 |
Total Current Assets | 423 | 312 | 319 | 437 | 402 |
Net Property & Equipment | 12 | 6 | 6 | 9 | 11 |
Investments & Advances | 0 | 29 | 108 | 33 | 65 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 11 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 5 | 1 | 1 | 1 |
Total Assets | 462 | 375 | 439 | 486 | 490 |
Liabilities & Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 6 | 10 | 6 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 18 | 21 | 22 | 14 | 16 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 35 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 63 | 30 | 36 | 24 | 23 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 160 | 0 | 1 | 1 | 3 |
Minority Interest (Liabilities) | 1 | 1 | 2 | 1 | 2 |
Total Liabilities | 246 | 54 | 39 | 31 | 27 |
Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 425 | 398 | 351 | 327 | 298 |
Retained Earnings | -207 | -73 | 49 | 128 | 164 |
Other Equity | -1 | -4 | 0 | 1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 217 | 321 | 399 | 456 | 462 |
Total Liabilities & Shareholder's Equity | 462 | 375 | 439 | 486 | 490 |
Total Common Equity | 217 | 321 | 399 | 456 | 462 |
Shares Outstanding | 21.00 | 20.70 | 20.20 | 20.00 | 19.60 |
Book Value Per Share | 10.32 | 15.52 | 19.77 | 22.78 | 23.60 |
Fiscal Year End for Enanta Pharmaceuticals, Inc falls in the month of September.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 337 | 370 | 387 | 210 |
Receivables | NA | 40 | 40 | 45 | 47 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 13 | 13 | 17 | 14 |
Total Current Assets | NA | 390 | 423 | 448 | 271 |
Net Property & Equipment | NA | 12 | 12 | 12 | 11 |
Investments & Advances | NA | 0 | 0 | 6 | 15 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 5 | 5 | 5 | 5 |
Total Assets | NA | 429 | 462 | 495 | 326 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 9 | 4 | 8 | 12 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 12 | 18 | 18 | 15 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 37 | 35 | 37 | 0 |
Total Current Liabilities | NA | 62 | 63 | 68 | 32 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 160 | 165 | 0 | |
Minority Interest (Liabilities) | NA | 1 | 1 | 1 | 1 |
Total Liabilities | NA | 237 | 246 | 257 | 57 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 433 | 425 | 418 | 411 |
Retained Earnings | NA | -240 | -207 | -179 | -140 |
Other Equity | NA | -1 | -1 | -2 | -2 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 192 | 217 | 238 | 269 |
Total Liabilities & Shareholder's Equity | NA | 429 | 462 | 495 | 326 |
Total Common Equity | 0 | 192 | 217 | 238 | 269 |
Shares Outstanding | 21.10 | 21.10 | 21.00 | 21.00 | 21.00 |
Book Value Per Share | 0.00 | 9.09 | 10.32 | 11.32 | 12.83 |